Zasper 20 mg (Capsule (Enteric Coated))

Indications

• Relief from chronic heartburn symptoms
• Healing of erosive esophagitis
• Maintenance of healing of erosive esophagitis
• Eradication of Helicobacter pylori infection
• Treatment of Zollinger-Ellison Syndrome
• Management of acid related Dyspepsia
• Healing of Duodenal & Gastric ulcer

Pharmacology

• Proton pump inhibitor
• Suppression of gastric acid secretion
• Specific inhibition of the H+/K+-ATPase
• Better acid control than racemic proton pump inhibitors
• Enteric-coated pellet formulation of esomeprazole magnesium
• Peak plasma levels at approximately 1.5 hours
• Metabolized in the liver by CYP enzymes
• Plasma protein binding of 97%
• Plasma elimination half-life of approximately 1-1.5 hours
• Combination Therapy with Antimicrobials

Dosage

• Oral dosage form
• IV Injection or IV infusion
• Different dosage regimens for various indications
• Oral Suspension instructions
• IV Injection preparation
• Pediatric dosage specifications
• Dosage for risk reduction of rebleeding of Gastric or Duodenal Ulcers

Administration

• Tablet or capsule should be swallowed whole
• Oral Suspension administration
• IV Injection solution preparation
• IV Injection administration guidelines

Interaction

• Metabolism by CYP2C19 and CYP3A4
• No clinically relevant interactions with specific CYP enzymes expected
• Potential interference with CYP2C19
• Possible interference with absorption of certain drugs
• Lack of change in pharmacokinetic profile with certain co-administered drugs

Contraindications

• Known hypersensitivity to any of the formulation

Side Effects

• Headache
• Diarrhoea
• Nausea
• Flatulence
• Abdominal pain
• Constipation
• Dry mouth

Pregnancy & Lactation

• Lack of adequate and well-controlled studies in pregnant women
• No teratogenic effects in animal studies
• Unstudied excretion of esomeprazole in milk
• Recommendation to discontinue breastfeeding if essential

Precautions & Warnings

• Symptomatic response to therapy does not preclude the presence of gastric malignancy
• Specific patient information for capsule administration
• Use of antacids while taking Zasper
• Lack of established safety and effectiveness in pediatric patients

Use in Special Populations

• Lack of established safety and effectiveness in pediatric patients
• Similar safety and efficacy in elderly and younger individuals
• No dosage adjustment recommended for mild to moderate hepatic insufficiency
• Unaltered pharmacokinetics in patients with renal impairment

Overdose Effects

• Acute toxicity signs in animal studies
• Absence of reported overdoses in humans
• Lack of specific antidote
• Symptomatic and supportive treatment recommended
• Expected minimal removal by dialysis

Storage Conditions

• Storage temperature not exceeding 30°C
• Protection from light and moisture
• Keep out of reach of children

Chemical Structure

• Molecular Formula: C17H19N3O3S
• Chemical Structure image available

Common Questions about Zasper 20 mg Capsule

• Mechanism of action description
• Variety of medicinal uses
• Common reported side effects
• Relevance to use during pregnancy or breastfeeding
• Timeline for onset of action

Related Brands

• Zasper 40 mg (Capsule (Enteric Coated)) - maks-drug-limited
• Zasper 40 mg/vial (IV Injection) - maks-drug-limited
• Esonaaf 40 mg (Capsule (Enteric Coated)) - naafco-pharma-ltd
• Nexven 20 mg (Capsule (Enteric Coated)) - c2c-pharma-ltd